Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

Participants needed: 1,350
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jul 13, 2026Locations: 361
Eligibility criteria

Males or non-pregnant females aged between 18 and 80 years (inclusive) at time o... [+2]

Chronic liver diseases other than MASH [+4]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Participants needed: 762
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jul 13, 2026Locations: 317
Eligibility criteria

Males or non-pregnant females aged between 18 and 75 years (inclusive) at time o... [+3]

Liver disorder other than MASH. [+5]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Participants needed: 762
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jun 4, 2026Locations: 303
Eligibility criteria

Males or non-pregnant females aged between 18 and 75 years (inclusive) at time o... [+3]

Liver disorder other than MASH. [+5]

Read more
Status: Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

Participants needed: 1,350
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jun 4, 2026Locations: 349
Eligibility criteria

Males or non-pregnant females aged between 18 and 80 years (inclusive) at time o... [+2]

Chronic liver diseases other than MASH [+4]

Read more